The long-term vision of CURE is to develop respiratory phage therapies capable of improving clinical outcomes in asthma. Such accomplishment will undoubtedly be paralleled by an enhanced understanding of microbiome variability in asthma, providing an innovative aspect of disease pheno/endotyping and establishing the basis for precision medicine interventions. Furthermore, the developed paradigm could be straightforwardly expanded to other chronic respiratory conditions, such as chronic obstructive pulmonary disease (COPD).

​

​Our vision requires the capacity to predict with accuracy and repeatability the microbiological, immunological and clinical effects of  an ecological intervention in the respiratory niche. We envision this approach as an integral part of phage therapy development, able to support decision making in preparation of phages mixes (‘cocktails’) and bridging the gap between the need for personalized treatment and regulatory demands for standardization.

 

​